Hikal slips 21% in one week, hits fresh 52-week low on disappointing Q4
The inflationary pressures and a sharp rise in input costs of raw material, energy and solvents, the management expects industry growth to be tapered and margins to be contract in the current fiscal.
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of conference call to discuss the financial and operational performance for the quarter and financial year ended March 31, 2022 Q4FY22 Quarterly Result Announced for Hikal Ltd.
Pharmaceuticals firm Hikal declares Q4FY22 result: Recommended a final dividend of Rs 0.40 per share (20% of FV); Total dividend for FY22 stands at Rs 1.60 per share (80% of FV) Revenue of Rs. 1,943 crore; YoY growth of 13% EBITDA of Rs. 341 crore; YoY growth of 5% PAT of Rs. 161 crores; YoY growth of 21% Capital expenditure to build a production facility at Panoli, Gujarat has initiated as part of 10-year multi-product animal health contract Traction from global innovator companies continued for CDMO segment of Pharmaceuticals and Crop Protection businesses Business excellence program is in progress with an aim to achieve higher throughput and lower cost of production from existing assets. Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said, “For the financial year ’22, we achieved a PAT of Rs 161 Crores, which is a growth of 21% as compared to last financial year. Our Board of Directors has recommended a final dividend of Rs 0.40 per share (20% of FV). Along with an interim dividend of Rs. 1.20 per share (60% of FV) declared in February 2022, the total dividend for FY22 stands at Rs 1.60 per share (80% of FV). On 6th Jan 2022, an unfortunate incident occurred at Sachin GIDC, Surat. Allegations were made that the tanker involved was carrying a by-product which allegedly came from Hikal’s Taloja factory. All relevant employees of Hikal have voluntarily co-operated in the ongoing investigation. Since then, there has been a judicial recognition of the non-existent role of Hikal and its employees in the entire incident, as elucidated by the Hon’ble Gujarat High Court in its order. The matter is still sub-judice and presently the Company is in a very strong legal position. As a result of the Sachin GIDC incident the MPCB had given a closure notice to the Taloja factory. We have provided all the documents to MPCB and are confident of resolving the issue on the closure notice at the earliest. The revenue for pharmaceutical business saw a muted growth of 3% and stood at Rs. 307 Crores in Q4 FY22. It was in line with the recent trend witnessed by the API industry due to strong transient headwinds of softening demand and disruptions in global supply chains. This combined with the challenging raw material disruptions and significant increase in input costs has seen a pressure on our margins in Q4 which we expect to continue through the first half of the year. On a positive side, we continued to receive new inquiries from global innovator companies in the CDMO business segment. We expect this segment to be a lead growth driver in the next few years. The Crop Protection business revenue stood at Rs 194 Crores in Q4 FY22. We continued to face raw material availability challenges for some of our key products. However, the demand remains strong in the market. We will continue developing alternate domestic suppliers to mitigate future supply chain disruptions. We are investing in new capacity addition, which is expected to come on stream in second half of this financial year. On the CDMO front, we continued receiving several new inquiries and are working on a portfolio of new products for global innovator companies. This year has marked the beginning of our strategic transformation journey, ‘Pinnacle Program’. The program is seeing good momentum along with positive changes across both businesses. Along with a leading management consultant, we have developed a clear set of priorities for the growth of our Company over next five years through a new strategic direction. This will help reach our bold aspiration of driving profitable as well as sustainable growth and transforming our business to go from ‘Good to Great’. As the industry faces strong headwinds due to the inflationary pressures and a sharp rise in input costs of raw material, energy and solvents, we expect growth to be tapered and margins to be contract in the next year. We will continue to focus on passing through increased input costs to our customers. However, we do expect longer lead times given the inflationary pressures even customers are facing. To counteract the challenging environment, we continue to undertake multiple cost reduction as well as operational efficiency improvement initiatives within our business excellence program to minimize the impact of rising cost on our margins. We expect FY 2022-23 to be a challenging year, one of consolidation and the following year we will return to sustainable and profitable growth”. Result PDF HIKAL LTD. - 524735 - Board recommends Final Dividend
Hikal Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2022, inter alia, has recommended Final Dividend for the financial year 2021-22 on equity share capital @ 20% [Re. 0.40/- per equity share, nominal value of Rs. 2/- each], aggregating to dividend of 80% (Rs. 1.60/- per equity share) {including Interim Dividend of Rs. 1.20/- per share (One Rupee Twenty paise only) (60%) paid to the shareholders in the month of March, 2022},subject to the approval of shareholders in the ensuing Annual General Meeting (AGM).Final Dividend, if approved by the shareholders at the ensuing AGM, will be paid within 30 days of the AGM date. HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Earnings Press Release - on the financial Results of the Company for the quarter and financial year ended March 31, 2022 HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation of the Company on the financial results pertaining to quarter and financial year ended March 31, 2022 HIKAL LTD. - 524735 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of The Securities And Exchange Board Of India [Listing Obligations And Disclosure Requirements (LODR)] Regulations, 2015
The Board of Directors of the Company at its meeting held today i.e., May 28, 2022: - Approved the Standalone and Consolidated audited Financial Results for the quarter and financial year ended March 31, 2022, and - Recommended Final dividend on the Equity Shares of the Company for the financial year 2021-22. HIKAL LTD. - 524735 - Financial Results For The Quarter And Financial Year Ended March 31, 2022
Audited Standalone And Consolidated Financial Results For The quarter and financial year ended March 31, 2022 
